How much does Daklinza cost?
Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on March 1, 2021.
When Daklinza (daclatasvir) was on the market, the wholesale cost for a 12-week course was roughly $63,000, but patients paid a range of $72,000 to $75,000. Daklinza and the generic daclatasvir was discontinued by Bristol Myers Squibb in 2019 due to business reasons.
Daklinza (daclatasvir) was formerly approved for the treatment of chronic hepatitis C virus (HCV) in adults, in combination with sofosbuvir (brand name: Sovaldi), with or without ribavirin, in genotypes 1 and 3, including hard to treat HCV patients such as those with HIV-1 co-infection, advanced cirrhosis, or post-liver transplant recurrence of HCV.
Daklinza is classified as a HCV NS5A inhibitor.
- Important information about the discontinuation of Daklinza. Bristol Myers Squibb. Accessed March 1, 2021 at https://www.bms.com/patient-and-caregivers/our-medicines/discontinuation-of-daklinza.html
Related Medical Questions
- What are the new drugs for the treatment of hepatitis C?
- Does Mavyret cure hep C (HCV)? What is the success rate?
- Does Epclusa cure Hep C, what is the success rate?
- How much does Epclusa cost?
- Can you take antibiotics with Mavyret?
- How does Epclusa work in the body?
- What is the difference between Vosevi and Epclusa?
- Does Sovaldi cure hepatitis C?
- What's the difference between Viekira Pak and Viekira XR?
- What types of Hepatitis C does Mavyret treat?
- What type of Hepatitis C is Zepatier used to treat?
- What types of hepatitis C (HCV) does Vosevi treat?